Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

Yazar
Park, K.
Ozguroglu, M.
Barlesi, F.
Vansteenkiste, J. F.
Spigel, D.
Yang, J. C-H.
Bajars, M.
Ruisi, M.
Manitz, J.
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/154731
Koleksiyonlar